The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

@inproceedings{Lieu2013TheAO,
  title={The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer},
  author={Christopher H Lieu and Hoa Thi Tuyet Tran and Zhi-qin Jiang and Muling Mao and Michael J Overman and Edward Y S Lin and Cathy Eng and Jeffrey S. Morris and Lee M. Ellis and John V. Heymach and Scott Kopetz},
  booktitle={PloS one},
  year={2013}
}
BACKGROUND Circulating angiogenic factors are altered in patients with mCRC receiving bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into possible resistance mechanisms. METHODS PlGF, VEGF-A, VEGF-C, and VEGF-D were measured from two cohorts of patients. Sequential plasma samples were obtained from a discovery cohort of 42 patients treated with chemotherapy and bevacizumab. A validation cohort included plasma samples from a cross-sectional of 403… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

The biology of VEGF and its receptors

Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter
  • Nature Medicine
  • 2003
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL

Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2011
VIEW 1 EXCERPT

Placental growth factor upregulation is a host response to antiangiogenic therapy.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011
VIEW 1 EXCERPT